DK0755446T3 - Cardiotrophin og anvendelser deraf - Google Patents

Cardiotrophin og anvendelser deraf

Info

Publication number
DK0755446T3
DK0755446T3 DK95921220T DK95921220T DK0755446T3 DK 0755446 T3 DK0755446 T3 DK 0755446T3 DK 95921220 T DK95921220 T DK 95921220T DK 95921220 T DK95921220 T DK 95921220T DK 0755446 T3 DK0755446 T3 DK 0755446T3
Authority
DK
Denmark
Prior art keywords
chf
disorders
neurological
activity
isolated
Prior art date
Application number
DK95921220T
Other languages
English (en)
Inventor
Joffre Baker
Kenneth Chien
Kathleen King
Diane Pennica
William Wood
Original Assignee
Genentech Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/233,609 external-priority patent/US5534615A/en
Application filed by Genentech Inc, Univ California filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0755446T3 publication Critical patent/DK0755446T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK95921220T 1994-04-25 1995-04-06 Cardiotrophin og anvendelser deraf DK0755446T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/233,609 US5534615A (en) 1994-04-25 1994-04-25 Cardiac hypertrophy factor and uses therefor
US08/286,304 US5571893A (en) 1994-04-25 1994-08-05 Cardiac hypertrophy factor
PCT/US1995/004467 WO1995029237A1 (en) 1994-04-25 1995-04-06 Cardiotrophin and uses therefor

Publications (1)

Publication Number Publication Date
DK0755446T3 true DK0755446T3 (da) 2007-01-29

Family

ID=26927082

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95921220T DK0755446T3 (da) 1994-04-25 1995-04-06 Cardiotrophin og anvendelser deraf

Country Status (10)

Country Link
US (5) US5723585A (da)
EP (1) EP0755446B1 (da)
JP (1) JP3906314B2 (da)
AT (1) ATE339503T1 (da)
CA (1) CA2188017C (da)
DE (1) DE69535221T2 (da)
DK (1) DK0755446T3 (da)
ES (1) ES2276393T3 (da)
MX (1) MX9604985A (da)
WO (1) WO1995029237A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) * 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) * 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US5869274A (en) * 1995-08-09 1999-02-09 Zymed Laboratories, Inc. Immuno-histochemical method that reduces background staining
AU768995B2 (en) * 1996-02-14 2004-01-15 Genentech Inc. Cardiotrophin and uses therefor
JP2000504729A (ja) * 1996-02-14 2000-04-18 ジェネンテク・インコーポレイテッド カルジオトロフィンとその使用法
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
US6875567B1 (en) * 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US6610480B1 (en) * 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
ES2242597T3 (es) * 1999-01-21 2005-11-16 Genentech, Inc. Composiciones y procedimientos para el diagnostico y tratamiento de un tumor.
CA2365843A1 (en) * 1999-03-09 2000-09-14 Atlantic Biopharmaceuticals, Inc. Expression of human alpha-fetoprotein in mammalian cells
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
DK1255829T3 (da) 2000-02-11 2009-12-14 Genentech Inc Inhibitor af hepatocytvækstfaktoraktivator til anvendelse i modulation af angiogenese og kardiovaskularisering
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2002312411A1 (en) * 2001-06-07 2002-12-16 Proligo Llc Microcalorimetric detection of analytes and binding events
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ES2200646B1 (es) 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
DE602004026445D1 (de) * 2003-06-25 2010-05-20 Ottawa Health Research Inst Verwendung von cardiotrophin zur modulation der stammzellenproliferation
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
EP2195333A1 (en) * 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
EP2670424A4 (en) * 2011-02-01 2014-12-31 Fate Therapeutics Inc CARDIOTROPHINE-RELATED MOLECULES FOR ENHANCED THERAPEUTICS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552071A (en) * 1978-06-21 1980-01-09 Kuzumaki Ringiyou Kk Turnery working method and its device
JPS5520721A (en) * 1978-07-31 1980-02-14 Nippi:Kk Separation of biologically active material from hematopiesis tissue of domestic animal
US4339441A (en) * 1981-10-30 1982-07-13 Sumner M. Kalman Cardioactive factor
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4900811A (en) * 1983-07-21 1990-02-13 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
WO1990009399A1 (en) * 1989-02-15 1990-08-23 Ono Pharmaceutical Co., Ltd. New neurotrophic factor
US5215969A (en) * 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
JP2829755B2 (ja) * 1989-12-27 1998-12-02 株式会社第一ラジオアイソトープ研究所 抗ヒト心筋ｃプロテインモノクローナル抗体及び該抗体を産生するハイブリドーマ
JP2904935B2 (ja) * 1990-10-19 1999-06-14 武田薬品工業株式会社 神経栄養活性抑制物質
US5214031A (en) * 1990-05-09 1993-05-25 Yoko Uchida Growth-inhibitory factor obtained from human brain
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
JPH04124198A (ja) * 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
WO1992011026A1 (en) * 1990-12-21 1992-07-09 Case Western Reserve University Neuronal cholinergic differentiation factor
CA2109098C (en) * 1991-04-22 2005-08-09 Douglas E. Brenneman Activity-dependent neurotrophic factor
AU2010592A (en) * 1991-05-20 1992-12-30 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
PT100580A (pt) * 1991-06-12 1993-09-30 Regeneron Pharma Producao e recuperacao de neurotrofinas recombinantes
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
WO1994005788A1 (fr) * 1991-09-12 1994-03-17 Sumitomo Pharmaceuticals Company, Limited Peptide neurotrophique
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
EP0607247A1 (en) * 1991-10-01 1994-07-27 Genentech, Inc. Production of gpa neurotrophic factor
WO1993018065A1 (fr) * 1992-03-10 1993-09-16 Mochida Pharmaceutical Co., Ltd. Substance proteique physiologiquement active
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
EP1415994A1 (en) * 1992-06-04 2004-05-06 The University Of Southern California Retinal pigmented epithelium derived neurotrophic factor
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor

Also Published As

Publication number Publication date
ES2276393T3 (es) 2007-06-16
CA2188017C (en) 2010-09-28
ATE339503T1 (de) 2006-10-15
CA2188017A1 (en) 1995-11-02
DE69535221D1 (de) 2006-10-26
DE69535221T2 (de) 2007-09-13
MX9604985A (es) 1998-05-31
EP0755446B1 (en) 2006-09-13
US5679545A (en) 1997-10-21
WO1995029237A1 (en) 1995-11-02
JPH09512427A (ja) 1997-12-16
EP0755446A1 (en) 1997-01-29
US5627073A (en) 1997-05-06
JP3906314B2 (ja) 2007-04-18
US5723585A (en) 1998-03-03
US5571675A (en) 1996-11-05
US5624806A (en) 1997-04-29
AU697165B2 (en) 1998-10-01
AU2635395A (en) 1995-11-16

Similar Documents

Publication Publication Date Title
DK0755446T3 (da) Cardiotrophin og anvendelser deraf
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
WO1996018738A3 (en) PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
NO176049C (no) Analogifremgangsmåte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-II-reseptorer
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ATE188969T1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
NO985376L (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE3674246D1 (de) Behandlung von sauerem kohlenwasserstoffdestillat.
DE3886144D1 (de) Kodierung von Signalen.
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DE3887591D1 (de) Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen.
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
WO1997030146A3 (en) Cardiotrophin and uses therefor
UA15920A (uk) Аміди циклометілеh-1, 2-дикарбоhових кислот, які мають гіпотеhзивhу активhість
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
DE69734890D1 (de) Rdgb-proteine
DE68908010D1 (de) Methode zur erhaltung der aktivitaet von zeolit-katalysatoren.